Observational studyFuture oncology (London, England)2025
hsa-miR-144-3p and hsa-miR-4262 are exosomal biomarkers and function as tumor suppressors in HCMV positive brain tumor.
Observational study in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present retrospective observational study was designed to explore the expression deregulation of exosomal microRNAs, hsa-miR-144-3p, hsa-miR-4262, and related genes in brain tumor patients.
methodsExosomes were extracted from 400 brain tumor patients and 400 controls and characterized using DLS, TEM, and ELISA. Quantitative PCR was used to check the expression level of hsa-miR-144-3p, hsa-miR-4262, phosphatidylinositol-3-kinase (PI3K) and AKT kinase (AKT) in study cohort. CMV level in brain tumor patients was checked by quantifying UL83.
resultsData analysis showed significant deregulation of hsa-miR-144-3p (p < 0.0001), hsa-miR-4262 (p < 0.0001), PI3K (p < 0.0001), and AKT (p < 0.0001) in brain tumor patients. Conclusions: ROC curve analysis showed that deregulation of hsa-miR-144-3p, hsa-miR-4262, PI3K, and AKT may act as good diagnostic markers for brain tumor patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.